

Index

PHARMACOLOGICAL REVIEWS

Volume 28

1976

- Adrenergic innervation, brain vessels, 286; figure, 287
- Adrenolytic agents, effect on cochlear microphonic amplitude, 105
- Adrenomimetic agents, effect on cochlear microphonic amplitude, 105
- Aequorea*, occurrence of, 6
- Aequorin
calcium-activated photoprotein, 2, 3, 5
calcium concentration-effect relations for, 37; figures, 39, 44
molecular weight, estimates (table), 17
spent, calcium binding to, 51
- Agonists, cerebrovascular smooth muscle effects (table), 305
- Allen, David G. *See* Blinks *et al.*, 1
- Amine(s)
action on cerebral blood flow (table), 306
blood-brain barrier mechanisms to, 293
cerebral metabolism and, 298
cerebrovascular actions of, 301
deficit, reserpine action and, 191
enzymatic barrier mechanisms to, 294
mechanisms in cerebral circulation, 275
neuron systems, central, 290
precursors
blood-brain barrier mechanisms to, 293
enzymatic barrier mechanisms to, 294
- Aminergic mechanisms, involvement in cerebral circulation, 317
- Anatomy, cochlea, autonomic innervation of, 102
- Anthozoans, source of photoproteins, 4
- Antidepressants, tricyclic, cholestatic response to, 237
- Anxiety, effect on cerebral metabolism and blood flow, 326
- Atmospheric exposure of cerebral cortex, effect on blood-brain barrier function, 298
- Auditory system. *See also* Cochlea
- Auditory system
peripheral, pharmacology of transmission, 95
- Behavioral changes caused by drugs, effect on cerebral metabolism and blood flow, 326
- Behavioral studies on olivocochlear bundle, 111
- Beroë*, occurrence of, 7
- Berovin
calcium-activated photoprotein, 5
molecular weight, 20, 21
- Bertaccini, Giulio. Active polypeptides of nonmammalian origin, 127
- Bile duct ligation, cholestasis induced by, 214
- Bile flow, altered canicular, cholestatic effects, 243
- Bile salts, effects on hepatobiliary system, 217
- Biliary concretions, cholestasis, morphological feature, 255
- Biliary system, caerulein effects on, 145
- Bioluminescence
chemical nature, elucidation of, 8
of photoproteins, proposed reaction sequence (figure), 10
regeneration and, of photoproteins, possible cyclic sequence of events for (figure), 12
- Blinks, John R., Franklyn G. Prendergast and David G. Allen. Photoproteins as biological indicators, 1
- Blood, labyrinthine artery supply to ear, 97
- Blood-brain barrier
factors affecting function, 296
mechanisms to amines and amine precursors, 293
morphology, 293
- Blood flow, cerebral. *See* Cerebral blood flow and Cerebral circulation
- Blood gas tensions, changing, reactivity of cerebral circulation to, 323
- Blood platelets, reserpine effect on 5-HT uptake, 190
- Blood vessels
bomesin-like peptides, action on, 143
bradykinins, action on, 140
brain, postganglionic autonomic innervation and other sources of amines (figure), 307
caerulein-like peptides, action on, 143
peptides, action on, 140
tachykinins, action on, 142
- Blood volume technique, cardiovascular reactivity assessment, 281
- Bobbin, Richard P. *See* Guth *et al.*, 95
- Bombesin-like peptides, 131, 138; table, 138
action on blood vessels, 143
clinical applications, 165
- Bradykinins, 128
action on blood vessels, 140
clinical applications, 162
sources (table), 129
structure-activity relationships, 132; table, 133

- Brain**
 isolated, perfused, cardiovascular reactivity assessment, 279
 metabolism, amines and, 298
Brain stem, effects of stimulation, 315; figure, 316
Brain tissue, retraction of, effect on blood-brain barrier function, 298
Brain vessels
 innervation of, 286
 postganglionic autonomic innervation and other sources of amines (figure), 307
Brunners glands, caerulein effects on secretions from, 150
- 1, 3-bis(2-Chloroethyl)1-nitrosourea, hepatotoxic effects, 242
- Caerulein**
 action on gastrointestinal motility, 145; table, 146
 stimulant effect (table), 165
Caerulein-like peptides
 action on blood vessels, 143
 clinical applications, 163
 structure-activity relationships, 136; table, 136
- Calcium**
 -activated photoproteins. *See* Photoproteins, calcium-activated
 in biological systems, photoproteins as indicators of, 1
 ionic, binding to photoproteins, 49
- Canicular bile flow**, altered, factor in cholestasis, 243
- Canicular membrane function**, changes during cholestasis, 246
- Central nervous system**, kinins action on, 160
- Cerebral blood flow**
 action of amines (table), 306
 effects of sympathetic nerve stimulation and noradrenaline (table), 304
 neuronal activity and, relationship, 327
- Cerebral circulation**
 amine mechanisms in, 275
 autoregulation
 aminergic mechanisms, 317
 changing arterial and intracranial pressure, 317
 cholinergic mechanisms, 319
 chronic hypertension, 320
 Shy-Drager syndrome, 320
 sympathetic nervous system, role, 320; figure, 321
- Cerebral circulation**
 effects of functional activity, 325
 reactivity of, to changing blood gas tensions, 323
 relationship between blood flow and metabolism, (figure), 324
- Cerebrospinal fluid formation**, intracranial pressure and, 325
- Cerebrovascular actions of amines**, 301
- Cerebrovascular reactivity**
 assessment
 autoradiography techniques, 281
 blood volume techniques, 281
 electromagnetic flowmetry techniques, 280
 freely diffusible tracer techniques, 283
in vitro models, 276
 isolated perfused brain techniques, 279
 methods of, 276
 microsphere techniques, 280
 oxygen electrodes, AV oxygen techniques, 282
 pial calibre techniques, 278
 thermal techniques, 283
 venous outflow techniques, 279
- Cerebrovascular smooth muscle**, effects of agonists (table), 305
- Cholestasis**
 altered canalicular bile flow, 243
 altered ductular cell permeability, 249
 bile salt biosynthesis from cholesterol, simplified pathways (figure), 251
 biliary concretions, 255
 canalicular membrane function, 246
 drugs with potential to cause, 209; table, 212
 experimental studies, 213
 α -naphthylisothiocyanate (ANIT), 220
 bile duct ligation, 214
 bile salts, 217
 erythromycins, 235
 manganese, 239
 phenothiazines, 237
 steroids, 231
 tricyclic antidepressants, 237
 hypotheses on mechanisms leading to, 243
 impaired mitochondrial function, 249
 intrahepatic
 induced by drugs and chemicals, 207
 review of literature, 209
 reactive metabolites, 257
 smooth endoplasmic reticulum function, and monohydroxy bile salts, factor in etiology of, 250
- Cholinergic innervation**, brain vessels, 286
- Cholinergic neuroeffector transmission**, embryonic heart, 352
- Cholinolytic drugs**
 influence on cochlear electrical activity, 105
 effect on cerebral circulation, 310
- Cholinomimetic drugs**
 influence on cochlear electrical activity, 105
 effects on cerebral circulation, 310
- Chromophore in photoproteins**, distinguished from luciferins, 8
- Circulation**
 cerebral. *See* Cerebral circulation
- Cochlea**. *See also* Auditory system
 afferent system, physiology of, 99
 afferent transmission, 98
 pharmacology of, 100
 anatomy of primary afferent synapse, 98
 autonomic innervation, 102

- anatomy, 102
 pharmacology, 105
 blood supply to, 97
 lateral line organs of lower animals analogous to, 119
Cochlear pharmacology
 glossary of terms, 96
 methods, 96
Coelenterate, luminescent marine, source of calcium-sensitive photoproteins, 4
Contrast media, effect on blood-brain barrier function, 297
Cranial nerve VII, stimulation and section of, 309

4, 4'-Diaminodiphenylmethane, contaminant which caused "Epping jaundice," 242
Dopamine effect on cerebral circulation, 313
Dopamine- β -hydroxylase, reserpine effects on, 198
Ductular cell permeability, altered, effect on cholestasis, 249

2-Ethyl-2-phenyl butyramide, cholestatic effects, 242
Ear. See Auditory system, Cochlea
Edvinsson, Lars, and Eric T. MacKenzie. Amine mechanisms in the cerebral circulation, 275
Electrocautery effect on blood-brain barrier function, 298
Electromagnetic flowmetry technique, cardiovascular reactivity assessment, 280
Energy transfer from photoprotein to green fluorescent protein, 15
Enzymatic barrier mechanisms to amines and amine precursors, 294
Enzymes, reserpine effects on, 198
"Epping jaundice," caused by 4, 4'-diaminodiphenylmethane, 242
Erythromycins
 cholestatic potential, 235
 derivatives, structures of (table), 236
***Escherichia coli*, cholestatic effects, 243**
Etioluciferin, chemical structure (figure), 9

Feces, reserpine elimination in, 199
Freely diffusible tracer technique, cardiovascular reactivity assessment, 283

Gastrointestinal hormone-like activity of peptides, 144
Gastrointestinal tract, caerulein effects on, 146
Green fluorescent protein (GFP), 5
 energy transfer to, from photoprotein, 15
Guth, Paul S., Charles H. Norris and Richard P. Bobbin. The pharmacology of transmission in the peripheral auditory system, 95

***Halistaura*, occurrence of, 7**
Halistaurin, calcium-activated photoprotein, 5

Hormone-like activity, gastrointestinal, of peptides, 144
Hormones, polypeptides role in release of, 152
Histamine effect on cerebral circulation, 314
5-Hydroxytryptamine effect on cerebral circulation, 311
Hypercapnia effect on blood-brain barrier function, 297
Hypertension effect on blood-brain barrier function, 297
Hypertonicity effect on blood-brain barrier function, 297

Innervation, brain vessels, 286
Intellectual effort, effect on cerebral metabolism and blood flow, 327
Intracranial pressure, cerebrospinal fluid formation and, 325

Kidney, reserpine elimination by, 199

Lateral line organs of lower animals, efferent innervation of, 119
Liver
 caerulein effects on secretions from, 151
 intrahepatic cholestasis induced by drugs and chemicals, 207
Luciferin, chemical structure (figure), 9
 heat stable fraction of bioluminescent systems, 8
Luciferase, heat labile fraction of bioluminescent systems, 8
Luminescence
 calcium-activated photoproteins, 7
 control, *in vivo*, 16
 ions that inhibit, 31
 ions that trigger, 25
 measurement of, 66
 interpretation of, 83
 of photoproteins, possible mechanisms of (figure), 14

MacKenzie, Eric T. See Edvinsson and MacKenzie, 275
Manganese, liver changes after administration of, 239
Mast cells, reserpine effect on 5-HT uptake in, 191
Metabolism
 cerebral, amines and, 298
 reserpine, 194
Metabolite, reactive, in cholestasis, 257
Microsphere technique, cardiovascular reactivity assessment, 280
Mitochondrial function, impaired, role in cholestasis, 249
Monoamine oxidase, reserpine effect on, 298
Monohydroxy bile salts, smooth endoplasmic reticulum function and, factor in etiology of cholestasis, 250

- Mnemiopsin**
 calcium-activated photoprotein, 5
 molecular weight, 20, 21
Mnemiopsis, occurrence of, 7
- α -Naphthylisothiocyanate (ANIT)**, cholestatic response to, 220
- Neurons**, central amine, 290
- Nitrofurantoin**, hepatic effects, 242
- Noradrenaline**, effect on cerebral blood flow (table), 304
- Norris**, Charles H. *See* Guth *et al.*, 95
- Novobiocin**, cholestatic potential, 242
- Obelia**, occurrence of, 6
- Obelin**
 calcium-activated photoprotein, 5
 calcium sensitivity, 42
 molecular weight, 20, 21
- Olivocochlear bundle**
 anatomy, 107
 behavioral studies on, 111
 pharmacology of, 111
 physiology of, 109
 transmitter substances, criteria for, 112
- Oxygen electrodes**, AV oxygen technique, cardiovascular reactivity assessment, 282
- Oxyluciferin**, chemical structure (figure), 9
- Pancreas**, caerulein effect on secretions from, 150
- Parasympathetic innervation**
 brain vessels, 289
- Peptides**. *See also* Polypeptides
 action on blood vessels, 140
 bombesin-like, 131, 138; table, 138
 bradykinins, 128
 structure-activity relationships, 132; table, 133
 caerulein-like, 131
 structure-activity relationships, 136; table, 136
 gastrointestinal hormone-like activity, 144
 physalaemin-like (tachykinins), 134
 tachykinins, 130
 structure-activity relationships, 134; table, 134
- Phenothiazines**, cholestasis associated with clinical use of, 237
- Photoproteins**
 biological calcium indicators, 1
 bioluminescence and regeneration, possible cyclic sequence of events for (figure), 12
 calcium-activated
 aequorin, 2, 3, 5
 berovin, 5
 bioluminescent reaction, nature of, 7
 features of, 4
 halistaurin, 5
 mnemiopsin, 5
 obelin, 5
 occurrence of, 4
 calcium
 binding, 49
 concentration influence on reaction rate, 37
 contamination, control of, 52
 detection in biological systems, 1
 measurement in biological systems, 70
 chromophore, chemical structure (figure), 9
 consumption, limiting rate constant for, 36
 desalting, 61
 energy transfer and green fluorescence, 15
 extraction, 53
 heterogeneity, 24
 introduction into cells, 63
 ionic specificity, 25
 kinetics, 36
 luminescent reaction, possible mechanisms of (figure), 14
 lyophilization, 61
 physicochemical properties, 17
 proposed reaction sequence for bioluminescence of (figure), 10
 purification, 55
 aequorin, 60
 mnemiopsin, 59
 procedures, 56
 purity, criteria for, 60
 "recharging" of, 11
 stability, factors affecting, 34
 stoichiometry, 36
 storage, 61
 undischarged, possible forms of chromophore in (figure), 13
 Physalaemin-like peptides (tachykinins), 134
 Pial calibre technique, cardiovascular reactivity assessment, 278
 Plaa, Gabriel L. and Brian G. Priestly. Intrahepatic cholestasis induced by drugs and chemicals, 207
 Polypeptides. *See also* Peptides
 active, of nonmammalian origin, 127
 miscellaneous, 131
 nonmammalian
 occurrence in nature, 127
 pharmacological actions, 139
 relative potency, on smooth muscle preparations, 157; table, 159
 role, in release of hormones, 152
 Prendergast, Franklyn G. *See* Blinks *et al.*, 1
 Priestly, Brian G. *See* Plaa and Priestly, 207
 Protein
 green fluorescent. *See* Green fluorescent protein (GFP)
 photo-. *See* Photoproteins
 Pulmonary excretion of reserpine, 200
- Rauwolfia**
 alkaloids, structural properties, 181

- historical review, 180
- tertiary indole alkaloid with carboxylic ring E (figure), 181
- Rauwolfia serpentina*, reserpine and reserpine-like alkaloids isolated from (figure), 181
- Reserpine**
 - absorption, 185
 - accumulation, theories of, 192
 - action of, and amine deficit, 191
 - adrenergic tissue, binding in, 187
 - analysis, methods of, 183
 - binding
 - effect on 5-HT uptake in blood platelets, 190
 - effect on 5-HT uptake in mast cells, 191
 - chemical nature, 192
 - to 5-HT cells, 190
 - to membrane lipids, 193
 - strength and permanence of, 192
 - biological fate, 179
 - chemical properties, 183
 - chemistry of, 181
 - distribution in tissue, 186
 - effects on enzymes, 198
 - excretion of, 198
 - fecal elimination of, 199
 - historical review, 180
 - hydrolytic cleavage of (figure), 183
 - metabolism of, 194
 - in vitro* microsomal, 196
 - physical properties, 183
 - pulmonary excretion of, 200
 - renal elimination of, 199
 - reserpine-like alkaloids and, isolated from *Rauwolfia serpentina*, 181
 - subcellular binding studies, 188
 - synthetic agents with reserpine-like activity (figure), 182
- Rifampicin, cholestatic potential, 242
- Secretions**
 - exocrine, peptides action on, 160
 - gastrointestinal, caerulein effects on, 149
- Shy-Drager syndrome, role of autonomic innervation of cerebral circulation, 320
- Sleep, effect on cerebral metabolism and blood flow, 326
- Smooth endoplasmic reticulum function, monohydroxy bile salts and, factor in etiology of cholestasis, 250
- Steroids**
 - cholestatic reaction to, 231
 - structural formulae of potentially cholestatic (table), 232
- Stitzel, Robert E. The biological fate of reserpine, 179
- Stomach, caerulein effect on secretions from, 149
- Stress, effect on cerebral metabolism and blood flow, 326
- Sucrose acetate isobutyrate, cholestatic effect, 242
- Sympathetic agents, effect on cerebral blood flow, 304
- Sympathetic innervation
 - brain vessels, 286; figure, 287
- Sympathetic nerve
 - stimulation, effect on cerebral blood flow (table), 304
 - stimulation and denervation experiments, 301
- Sympathetic nervous system, role in autoregulation of cerebral blood flow, 320; figure, 321
- Sympatholytic agents, effect on cerebral blood flow, 304
- Tachykinins**
 - action on blood vessels, 142
 - clinical applications, 163
 - sources (table), 130
 - structure-activity relationships, 134; table, 134
- Tetrabenazine studies, reserpine binding in adrenergic tissue, 187
- Thermal technique, cardiovascular reactivity assessment, 283
- Tricyclic antidepressants, cholestasis associated with clinical use of, 237
- Tyrosine hydroxylase, reserpine effects on, 198
- Venous outflow technique, cardiovascular reactivity assessment, 279

Forthcoming Articles

Cholinergic Systems in Non-Nervous Tissue. *B. V. Rama Sastry*

Histamine H₂ Receptors: Activation and Antagonism. *J. W. Black*

Ontogenic Development of Autonomic Neuroeffector Transmission and Transmitter Reactivity in Embryonic and Fetal Hearts. *Achilles J. Pappano*

Drug-Induced Alterations of Ion Distribution at the Cellular Level of the Central Nervous System. *Leif Hertz*

The Role of the Nervous System in the Cardiovascular Effects of Digitalis. *Richard A. Gillis and John A. Quest*

Suggestions to Contributors will be found in PHARMACOLOGICAL REVIEWS, 28, i-ii, 1976, and reprints may be obtained on request from the Editorial Office, Route 3, Box 229, Sylvania, Georgia 30467.

PHARMACOLOGICAL REVIEWS

VOLUME 28
NUMBER 4
December 1976

A quarterly publication in pharmacology, experimental therapeutics, and chemotherapy published for the **American Society for Pharmacology and Experimental Therapeutics, Inc.**, under the supervision of the Board of Publications Trustees: JAMES A. BAIN, *Chairman*, DANIEL L. AZARNOFF, MARION DEV. COTTEN, GEORGE I. DRUMMOND, KENNETH C. LEIBMAN, GILBERT J. MANNERING, JEAN McE. MARSHALL, WALTER MODELL, IRWIN M. WEINER

The editorial supervision of Pharmacological Reviews is shared jointly with the **British Pharmacological Society** and the **Scandinavian Pharmacological Society**.

Chairman

MARION DEV. COTTEN

ADRIEN ALBERT

ERVIN G. ERDÖS

ALFRED HELLER

L. L. IVERSEN

D. H. JENKINSON

WERNER KALOW

MATTI K. PAASONEN

ROGER F. PALMER

DAVID P. RALL

JENS SCHOU

D. F. SHARMAN

Executive Officer

ELLSWORTH B. COOK